 Sarah Billups
Concepts (281)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Pharmacists | 19 | 2025 | 265 | 4.660 |
Why?
| | Osteoporosis | 4 | 2023 | 243 | 2.310 |
Why?
| | Osteoporotic Fractures | 3 | 2023 | 60 | 1.650 |
Why?
| | Bone Density Conservation Agents | 4 | 2022 | 80 | 1.610 |
Why?
| | Hypertension | 8 | 2025 | 1295 | 1.440 |
Why?
| | Primary Health Care | 13 | 2025 | 1738 | 1.430 |
Why?
| | Osteoporosis, Postmenopausal | 3 | 2022 | 42 | 1.220 |
Why?
| | Quality Improvement | 3 | 2025 | 1178 | 1.060 |
Why?
| | Gout Suppressants | 2 | 2025 | 20 | 1.060 |
Why?
| | Gout | 2 | 2025 | 37 | 1.030 |
Why?
| | Pharmaceutical Services | 7 | 2020 | 83 | 1.010 |
Why?
| | Antihypertensive Agents | 5 | 2025 | 494 | 1.000 |
Why?
| | Xanthine Oxidase | 1 | 2025 | 81 | 0.940 |
Why?
| | Remote Consultation | 1 | 2025 | 54 | 0.920 |
Why?
| | Medicare Part C | 1 | 2025 | 31 | 0.870 |
Why?
| | Guideline Adherence | 4 | 2025 | 556 | 0.830 |
Why?
| | Pharmacy Service, Hospital | 11 | 2017 | 90 | 0.780 |
Why?
| | Maternal Health Services | 1 | 2024 | 98 | 0.780 |
Why?
| | Blood Pressure | 3 | 2025 | 1786 | 0.760 |
Why?
| | Medication Adherence | 2 | 2025 | 467 | 0.760 |
Why?
| | Enzyme Inhibitors | 2 | 2025 | 840 | 0.760 |
Why?
| | Retrospective Studies | 24 | 2025 | 15657 | 0.720 |
Why?
| | Urinary Tract Infections | 1 | 2023 | 188 | 0.710 |
Why?
| | Communicable Diseases | 1 | 2023 | 159 | 0.710 |
Why?
| | Pre-Exposure Prophylaxis | 1 | 2023 | 213 | 0.690 |
Why?
| | Aged | 36 | 2025 | 23961 | 0.640 |
Why?
| | Blood Pressure Determination | 2 | 2018 | 157 | 0.640 |
Why?
| | Emergency Service, Hospital | 5 | 2023 | 2069 | 0.610 |
Why?
| | Patient-Centered Care | 1 | 2024 | 530 | 0.600 |
Why?
| | Cohort Studies | 11 | 2025 | 5742 | 0.580 |
Why?
| | Patient Transfer | 1 | 2020 | 176 | 0.560 |
Why?
| | Diphosphonates | 2 | 2015 | 66 | 0.560 |
Why?
| | Education, Pharmacy, Graduate | 2 | 2016 | 17 | 0.540 |
Why?
| | Anti-HIV Agents | 1 | 2023 | 778 | 0.520 |
Why?
| | Blood Pressure Monitoring, Ambulatory | 2 | 2014 | 85 | 0.520 |
Why?
| | Pharmacy Residencies | 1 | 2016 | 11 | 0.510 |
Why?
| | Community Pharmacy Services | 2 | 2013 | 45 | 0.500 |
Why?
| | Research | 2 | 2016 | 451 | 0.490 |
Why?
| | Aged, 80 and over | 11 | 2025 | 7635 | 0.470 |
Why?
| | Female | 45 | 2025 | 73304 | 0.470 |
Why?
| | Humans | 58 | 2025 | 137585 | 0.460 |
Why?
| | Telephone | 1 | 2015 | 173 | 0.440 |
Why?
| | Hospitals, Veterans | 9 | 2001 | 252 | 0.420 |
Why?
| | Pharmacies | 1 | 2014 | 38 | 0.420 |
Why?
| | Correspondence as Topic | 2 | 2015 | 15 | 0.410 |
Why?
| | Patient Satisfaction | 5 | 2013 | 660 | 0.410 |
Why?
| | Patient Compliance | 5 | 2009 | 581 | 0.400 |
Why?
| | Middle Aged | 27 | 2025 | 33479 | 0.400 |
Why?
| | Health Maintenance Organizations | 4 | 2014 | 108 | 0.380 |
Why?
| | Male | 40 | 2025 | 67762 | 0.380 |
Why?
| | Professional Role | 5 | 2020 | 167 | 0.380 |
Why?
| | Prescription Drugs | 1 | 2013 | 109 | 0.370 |
Why?
| | Colorado | 10 | 2025 | 4565 | 0.370 |
Why?
| | Delivery of Health Care, Integrated | 5 | 2018 | 261 | 0.360 |
Why?
| | Insurance, Health | 1 | 2014 | 283 | 0.360 |
Why?
| | Cost Savings | 2 | 2015 | 84 | 0.350 |
Why?
| | Neuromuscular Agents | 1 | 2011 | 35 | 0.340 |
Why?
| | Drug Prescriptions | 4 | 2020 | 245 | 0.330 |
Why?
| | Drug Therapy | 2 | 2000 | 85 | 0.320 |
Why?
| | Cytochrome P-450 CYP2D6 Inhibitors | 1 | 2009 | 3 | 0.310 |
Why?
| | Nortriptyline | 1 | 2009 | 10 | 0.310 |
Why?
| | Drug Monitoring | 6 | 2014 | 218 | 0.310 |
Why?
| | Amitriptyline | 1 | 2009 | 21 | 0.310 |
Why?
| | Antidepressive Agents, Tricyclic | 1 | 2009 | 30 | 0.310 |
Why?
| | Adult | 17 | 2025 | 37929 | 0.300 |
Why?
| | Antidepressive Agents, Second-Generation | 1 | 2009 | 45 | 0.300 |
Why?
| | HIV Infections | 1 | 2023 | 2836 | 0.290 |
Why?
| | Perception | 2 | 2023 | 359 | 0.290 |
Why?
| | Tetrahydronaphthalenes | 2 | 1998 | 29 | 0.290 |
Why?
| | Health Knowledge, Attitudes, Practice | 1 | 2016 | 1329 | 0.280 |
Why?
| | Calcium Channel Blockers | 2 | 1998 | 167 | 0.270 |
Why?
| | Benzimidazoles | 2 | 1998 | 170 | 0.270 |
Why?
| | Fractures, Bone | 1 | 2012 | 380 | 0.270 |
Why?
| | Practice Patterns, Physicians' | 4 | 2023 | 1313 | 0.260 |
Why?
| | Cholesterol, LDL | 2 | 2025 | 365 | 0.250 |
Why?
| | Pilot Projects | 2 | 2023 | 1710 | 0.250 |
Why?
| | Managed Care Programs | 2 | 2013 | 135 | 0.250 |
Why?
| | American Heart Association | 2 | 2020 | 306 | 0.240 |
Why?
| | Lovastatin | 1 | 2005 | 37 | 0.240 |
Why?
| | Simvastatin | 1 | 2005 | 61 | 0.240 |
Why?
| | United States | 15 | 2025 | 14841 | 0.230 |
Why?
| | Drug-Related Side Effects and Adverse Reactions | 4 | 2018 | 250 | 0.230 |
Why?
| | Heart Diseases | 1 | 2008 | 346 | 0.220 |
Why?
| | Patient Acceptance of Health Care | 2 | 2023 | 806 | 0.220 |
Why?
| | Ambulatory Care | 6 | 2010 | 546 | 0.220 |
Why?
| | Uric Acid | 1 | 2025 | 163 | 0.220 |
Why?
| | Hydroxymethylglutaryl-CoA Reductase Inhibitors | 3 | 2025 | 445 | 0.220 |
Why?
| | Health Care Costs | 2 | 2014 | 398 | 0.220 |
Why?
| | Academic Medical Centers | 2 | 2024 | 512 | 0.210 |
Why?
| | Wounds and Injuries | 1 | 2011 | 758 | 0.210 |
Why?
| | Migraine Disorders | 2 | 2020 | 102 | 0.210 |
Why?
| | Bone Density | 2 | 2022 | 489 | 0.210 |
Why?
| | Cholesterol | 2 | 2020 | 410 | 0.210 |
Why?
| | Gastrointestinal Hemorrhage | 1 | 2024 | 132 | 0.200 |
Why?
| | Absorptiometry, Photon | 1 | 2023 | 259 | 0.200 |
Why?
| | Patient Care Team | 3 | 2024 | 631 | 0.200 |
Why?
| | Denosumab | 1 | 2022 | 9 | 0.190 |
Why?
| | Pregnancy Outcome | 1 | 2024 | 416 | 0.180 |
Why?
| | Practice Guidelines as Topic | 3 | 2020 | 1587 | 0.180 |
Why?
| | Serotonin 5-HT1 Receptor Agonists | 1 | 2020 | 4 | 0.180 |
Why?
| | Aspirin | 1 | 2024 | 387 | 0.170 |
Why?
| | Analgesics, Opioid | 2 | 2020 | 1000 | 0.170 |
Why?
| | Atherosclerosis | 1 | 2025 | 415 | 0.170 |
Why?
| | Diabetes Mellitus | 2 | 2013 | 1040 | 0.170 |
Why?
| | Quality of Health Care | 1 | 2024 | 642 | 0.150 |
Why?
| | Pregnancy Complications | 1 | 2024 | 527 | 0.150 |
Why?
| | Student Health Services | 1 | 2018 | 15 | 0.150 |
Why?
| | Glucocorticoids | 1 | 2023 | 594 | 0.150 |
Why?
| | Lithium Compounds | 1 | 2018 | 12 | 0.150 |
Why?
| | Antimanic Agents | 1 | 2018 | 18 | 0.140 |
Why?
| | Angina Pectoris | 1 | 1998 | 65 | 0.140 |
Why?
| | Product Surveillance, Postmarketing | 1 | 1998 | 63 | 0.140 |
Why?
| | Referral and Consultation | 1 | 2023 | 786 | 0.140 |
Why?
| | Drug Approval | 1 | 1998 | 88 | 0.140 |
Why?
| | Preceptorship | 1 | 2018 | 66 | 0.140 |
Why?
| | Cardiovascular Diseases | 3 | 2025 | 2111 | 0.140 |
Why?
| | Young Adult | 5 | 2023 | 13209 | 0.140 |
Why?
| | Antidepressive Agents | 2 | 2017 | 236 | 0.140 |
Why?
| | Data Collection | 4 | 2014 | 673 | 0.130 |
Why?
| | Students, Pharmacy | 1 | 2018 | 97 | 0.130 |
Why?
| | Electronic Health Records | 3 | 2022 | 1069 | 0.130 |
Why?
| | Drug Interactions | 4 | 2012 | 410 | 0.130 |
Why?
| | Quality of Life | 4 | 2001 | 2892 | 0.130 |
Why?
| | Administration, Oral | 2 | 2015 | 816 | 0.120 |
Why?
| | Antipsychotic Agents | 1 | 2017 | 194 | 0.120 |
Why?
| | Monitoring, Physiologic | 1 | 2017 | 275 | 0.120 |
Why?
| | Pharmaceutical Preparations | 2 | 2016 | 179 | 0.120 |
Why?
| | Internship, Nonmedical | 1 | 2015 | 14 | 0.120 |
Why?
| | Cost-Benefit Analysis | 2 | 2015 | 591 | 0.110 |
Why?
| | Patient Readmission | 1 | 2020 | 697 | 0.110 |
Why?
| | Risk Factors | 10 | 2025 | 10388 | 0.110 |
Why?
| | Hematinics | 1 | 2014 | 22 | 0.110 |
Why?
| | United States Department of Veterans Affairs | 5 | 2001 | 678 | 0.110 |
Why?
| | Renal Insufficiency | 2 | 2015 | 162 | 0.110 |
Why?
| | Follow-Up Studies | 3 | 2013 | 5131 | 0.110 |
Why?
| | Patient Discharge | 1 | 2020 | 897 | 0.100 |
Why?
| | Educational Measurement | 1 | 2016 | 289 | 0.100 |
Why?
| | Reminder Systems | 1 | 2015 | 169 | 0.100 |
Why?
| | Anti-Bacterial Agents | 1 | 2023 | 1809 | 0.100 |
Why?
| | Decision Support Systems, Clinical | 1 | 2016 | 226 | 0.100 |
Why?
| | Colchicine | 1 | 2012 | 24 | 0.100 |
Why?
| | Outpatients | 1 | 2016 | 396 | 0.100 |
Why?
| | Lipids | 1 | 2017 | 672 | 0.100 |
Why?
| | Anemia | 1 | 2014 | 170 | 0.100 |
Why?
| | Hematologic Diseases | 1 | 2012 | 62 | 0.100 |
Why?
| | Diagnosis, Computer-Assisted | 1 | 2013 | 89 | 0.100 |
Why?
| | Health Expenditures | 1 | 2014 | 189 | 0.090 |
Why?
| | Cross-Sectional Studies | 4 | 2024 | 5472 | 0.090 |
Why?
| | Adolescent | 4 | 2023 | 21513 | 0.090 |
Why?
| | Hospitalization | 2 | 2018 | 2199 | 0.090 |
Why?
| | Drug Therapy, Combination | 2 | 2009 | 1066 | 0.090 |
Why?
| | Hyperlipidemias | 3 | 2017 | 120 | 0.090 |
Why?
| | Pregnancy | 1 | 2024 | 6763 | 0.090 |
Why?
| | Job Satisfaction | 1 | 2013 | 218 | 0.090 |
Why?
| | Chemical and Drug Induced Liver Injury | 1 | 2012 | 137 | 0.090 |
Why?
| | Evaluation Studies as Topic | 1 | 2011 | 180 | 0.090 |
Why?
| | Venous Thromboembolism | 1 | 2015 | 316 | 0.090 |
Why?
| | Chronic Disease | 4 | 2008 | 1793 | 0.090 |
Why?
| | Diazepam | 1 | 2010 | 35 | 0.080 |
Why?
| | Amiodarone | 1 | 2010 | 26 | 0.080 |
Why?
| | Anticoagulants | 1 | 2015 | 664 | 0.080 |
Why?
| | Diabetes Mellitus, Type 2 | 2 | 2022 | 2531 | 0.080 |
Why?
| | Depression | 2 | 2017 | 1397 | 0.080 |
Why?
| | Anti-Anxiety Agents | 1 | 2010 | 46 | 0.080 |
Why?
| | Ipratropium | 1 | 2009 | 6 | 0.080 |
Why?
| | Anti-Arrhythmia Agents | 1 | 2010 | 114 | 0.080 |
Why?
| | Case-Control Studies | 3 | 2018 | 3556 | 0.080 |
Why?
| | Paroxetine | 1 | 2009 | 11 | 0.080 |
Why?
| | Mental Disorders | 1 | 2018 | 1077 | 0.080 |
Why?
| | Cytochrome P-450 CYP2D6 | 1 | 2009 | 30 | 0.080 |
Why?
| | Bupropion | 1 | 2009 | 45 | 0.080 |
Why?
| | Heart Failure | 1 | 2022 | 2236 | 0.080 |
Why?
| | Time Factors | 4 | 2013 | 6828 | 0.070 |
Why?
| | Mibefradil | 2 | 1998 | 7 | 0.070 |
Why?
| | Fluoxetine | 1 | 2009 | 54 | 0.070 |
Why?
| | Telemedicine | 1 | 2017 | 862 | 0.070 |
Why?
| | Kidney | 1 | 2016 | 1468 | 0.070 |
Why?
| | Fees, Pharmaceutical | 1 | 2008 | 9 | 0.070 |
Why?
| | Internet | 1 | 2013 | 655 | 0.070 |
Why?
| | Bronchodilator Agents | 1 | 2009 | 252 | 0.070 |
Why?
| | Blood Glucose | 1 | 2017 | 2186 | 0.070 |
Why?
| | Prospective Studies | 5 | 2015 | 7604 | 0.070 |
Why?
| | Surveys and Questionnaires | 7 | 2018 | 5778 | 0.060 |
Why?
| | Tryptamines | 1 | 2006 | 5 | 0.060 |
Why?
| | Sumatriptan | 1 | 2006 | 8 | 0.060 |
Why?
| | Serotonin Receptor Agonists | 1 | 2006 | 26 | 0.060 |
Why?
| | Financing, Personal | 1 | 2005 | 26 | 0.060 |
Why?
| | Drugs, Generic | 1 | 2005 | 22 | 0.060 |
Why?
| | Hypolipidemic Agents | 2 | 2008 | 91 | 0.060 |
Why?
| | Triazoles | 1 | 2006 | 147 | 0.060 |
Why?
| | Drug Costs | 1 | 2005 | 106 | 0.060 |
Why?
| | Dose-Response Relationship, Drug | 1 | 2009 | 2057 | 0.060 |
Why?
| | Incidence | 1 | 2011 | 2804 | 0.050 |
Why?
| | Patients | 1 | 2005 | 175 | 0.050 |
Why?
| | Anticholesteremic Agents | 1 | 2005 | 153 | 0.050 |
Why?
| | Medical Records Systems, Computerized | 2 | 2006 | 96 | 0.050 |
Why?
| | Mass Screening | 1 | 2012 | 1287 | 0.050 |
Why?
| | Age Factors | 1 | 2011 | 3295 | 0.050 |
Why?
| | Proton Pump Inhibitors | 1 | 2024 | 109 | 0.050 |
Why?
| | Medicaid | 2 | 2017 | 435 | 0.050 |
Why?
| | Secondary Prevention | 1 | 2024 | 233 | 0.050 |
Why?
| | Sex Factors | 1 | 2009 | 2071 | 0.050 |
Why?
| | Primary Prevention | 1 | 2024 | 196 | 0.050 |
Why?
| | Sodium Potassium Chloride Symporter Inhibitors | 1 | 2022 | 16 | 0.050 |
Why?
| | Sodium | 1 | 2022 | 217 | 0.040 |
Why?
| | Pulmonary Disease, Chronic Obstructive | 1 | 2009 | 1040 | 0.040 |
Why?
| | Economics, Pharmaceutical | 1 | 2000 | 9 | 0.040 |
Why?
| | Treatment Outcome | 3 | 2006 | 10811 | 0.040 |
Why?
| | Platelet Aggregation Inhibitors | 1 | 2024 | 463 | 0.040 |
Why?
| | Medication Systems, Hospital | 1 | 1999 | 9 | 0.040 |
Why?
| | Ambulatory Care Facilities | 2 | 2017 | 232 | 0.040 |
Why?
| | Veterans | 2 | 2001 | 1476 | 0.040 |
Why?
| | Federal Government | 1 | 2018 | 28 | 0.040 |
Why?
| | Community Health Centers | 1 | 2018 | 60 | 0.040 |
Why?
| | Outpatient Clinics, Hospital | 1 | 1998 | 82 | 0.030 |
Why?
| | Renal Insufficiency, Chronic | 2 | 2014 | 617 | 0.030 |
Why?
| | Vulnerable Populations | 1 | 2018 | 163 | 0.030 |
Why?
| | Software | 2 | 1999 | 665 | 0.030 |
Why?
| | Glucose | 1 | 2022 | 1020 | 0.030 |
Why?
| | Counseling | 1 | 2000 | 391 | 0.030 |
Why?
| | Drug Dosage Calculations | 1 | 2016 | 23 | 0.030 |
Why?
| | Prescription Drug Misuse | 1 | 2017 | 41 | 0.030 |
Why?
| | Contraindications | 1 | 2016 | 90 | 0.030 |
Why?
| | Health Status | 1 | 2001 | 792 | 0.030 |
Why?
| | International Normalized Ratio | 1 | 2015 | 47 | 0.030 |
Why?
| | Logistic Models | 1 | 2000 | 2074 | 0.030 |
Why?
| | Epoetin Alfa | 1 | 2014 | 9 | 0.030 |
Why?
| | Warfarin | 1 | 2015 | 154 | 0.030 |
Why?
| | Longitudinal Studies | 2 | 2014 | 2844 | 0.030 |
Why?
| | Pain Management | 1 | 2017 | 352 | 0.030 |
Why?
| | Erythropoietin | 1 | 2014 | 95 | 0.030 |
Why?
| | Clinical Trials as Topic | 1 | 1998 | 1050 | 0.030 |
Why?
| | Publishing | 1 | 2015 | 147 | 0.030 |
Why?
| | Cytochrome P-450 CYP3A Inhibitors | 1 | 2012 | 18 | 0.020 |
Why?
| | Drug Overdose | 1 | 2017 | 347 | 0.020 |
Why?
| | Acute Disease | 1 | 2015 | 1007 | 0.020 |
Why?
| | Cytochrome P-450 CYP3A | 1 | 2012 | 88 | 0.020 |
Why?
| | Chi-Square Distribution | 1 | 2013 | 530 | 0.020 |
Why?
| | Recurrence | 1 | 2015 | 1060 | 0.020 |
Why?
| | Specialization | 1 | 2013 | 144 | 0.020 |
Why?
| | Insurance, Health, Reimbursement | 1 | 2012 | 99 | 0.020 |
Why?
| | Education, Pharmacy | 1 | 2013 | 120 | 0.020 |
Why?
| | Recombinant Proteins | 1 | 2014 | 1353 | 0.020 |
Why?
| | Commission on Professional and Hospital Activities | 1 | 2010 | 4 | 0.020 |
Why?
| | Hemorrhage | 1 | 2015 | 722 | 0.020 |
Why?
| | Thyrotropin | 1 | 2010 | 114 | 0.020 |
Why?
| | Alanine Transaminase | 1 | 2010 | 157 | 0.020 |
Why?
| | Opioid-Related Disorders | 1 | 2017 | 515 | 0.020 |
Why?
| | Nebulizers and Vaporizers | 1 | 2009 | 86 | 0.020 |
Why?
| | Data Interpretation, Statistical | 2 | 2001 | 363 | 0.020 |
Why?
| | Spirometry | 1 | 2009 | 281 | 0.020 |
Why?
| | Models, Econometric | 1 | 2008 | 34 | 0.020 |
Why?
| | Comorbidity | 1 | 2013 | 1622 | 0.020 |
Why?
| | Forced Expiratory Volume | 1 | 2009 | 531 | 0.020 |
Why?
| | Predictive Value of Tests | 1 | 2013 | 2031 | 0.020 |
Why?
| | Cardiology | 1 | 2010 | 274 | 0.020 |
Why?
| | Drug Utilization | 1 | 2008 | 169 | 0.020 |
Why?
| | Electrocardiography | 1 | 2010 | 629 | 0.020 |
Why?
| | Analgesics | 1 | 2008 | 206 | 0.020 |
Why?
| | Prevalence | 1 | 2012 | 2734 | 0.010 |
Why?
| | Prognosis | 1 | 2013 | 4030 | 0.010 |
Why?
| | Child, Preschool | 1 | 2017 | 11074 | 0.010 |
Why?
| | Pain | 1 | 2008 | 756 | 0.010 |
Why?
| | Reproducibility of Results | 2 | 1999 | 3284 | 0.010 |
Why?
| | Total Quality Management | 1 | 2001 | 61 | 0.010 |
Why?
| | Health Status Indicators | 1 | 2001 | 171 | 0.010 |
Why?
| | Lipoproteins, LDL | 1 | 2000 | 116 | 0.010 |
Why?
| | Quality-Adjusted Life Years | 1 | 2000 | 113 | 0.010 |
Why?
| | Multicenter Studies as Topic | 1 | 2001 | 310 | 0.010 |
Why?
| | Treatment Refusal | 1 | 2000 | 89 | 0.010 |
Why?
| | Diabetes Complications | 1 | 2001 | 227 | 0.010 |
Why?
| | Linear Models | 1 | 2001 | 849 | 0.010 |
Why?
| | Medical Records | 1 | 1999 | 177 | 0.010 |
Why?
| | Quality Indicators, Health Care | 1 | 2001 | 307 | 0.010 |
Why?
| | Health Services Research | 1 | 2001 | 404 | 0.010 |
Why?
| | Child | 1 | 2017 | 21935 | 0.010 |
Why?
| | Attitude to Health | 1 | 2001 | 439 | 0.010 |
Why?
| | Randomized Controlled Trials as Topic | 1 | 2001 | 1477 | 0.010 |
Why?
| | Patient Education as Topic | 1 | 2000 | 766 | 0.010 |
Why?
| | Sensitivity and Specificity | 1 | 1999 | 1946 | 0.010 |
Why?
| | Severity of Illness Index | 1 | 1999 | 2828 | 0.010 |
Why?
|
|
Billups's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|